ciprofloxacin has been researched along with Ventilator-Associated Pneumonia in 11 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis." | 7.79 | Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. ( Fruhwald, S; Grisold, AJ; Hoenigl, M; Ovcina, I; Valentin, T, 2013) |
| " In this patient, however, the clinical course was dramatically complicated by the development of ciprofloxacin-associated rhabdomyolysis." | 3.79 | Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. ( Fruhwald, S; Grisold, AJ; Hoenigl, M; Ovcina, I; Valentin, T, 2013) |
| "Levofloxacin (200 mg/kg) was 73% effective, and ciprofloxacin (35 mg/kg) was ineffective in preventing death." | 1.39 | Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients. ( Davies, TA; He, W; Lynch, AS; Queenan, AM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Reinhardt, A | 1 |
| Köhler, T | 1 |
| Wood, P | 1 |
| Rohner, P | 1 |
| Dumas, JL | 1 |
| Ricou, B | 1 |
| van Delden, C | 1 |
| Copur, B | 1 |
| Dosler, S | 1 |
| Aktas, Z | 1 |
| Basaran, S | 1 |
| Simsek-Yavuz, S | 1 |
| Cagatay, A | 1 |
| Oncul, O | 1 |
| Ozsut, H | 1 |
| Eraksoy, H | 1 |
| Attia, NM | 1 |
| Elbaradei, A | 1 |
| Tran, GM | 1 |
| Ho-Le, TP | 1 |
| Ha, DT | 1 |
| Tran-Nguyen, CH | 1 |
| Nguyen, TSM | 1 |
| Pham, TTN | 1 |
| Nguyen, TA | 1 |
| Nguyen, DA | 1 |
| Hoang, HQ | 1 |
| Tran, NV | 1 |
| Nguyen, TV | 1 |
| Grisold, AJ | 1 |
| Hoenigl, M | 1 |
| Ovcina, I | 1 |
| Valentin, T | 1 |
| Fruhwald, S | 1 |
| Queenan, AM | 1 |
| Davies, TA | 1 |
| He, W | 1 |
| Lynch, AS | 1 |
| Muscedere, JG | 1 |
| Shorr, AF | 2 |
| Jiang, X | 2 |
| Day, A | 2 |
| Heyland, DK | 2 |
| Medina, J | 1 |
| Formento, C | 1 |
| Pontet, J | 1 |
| Curbelo, A | 1 |
| Bazet, C | 1 |
| Gerez, J | 1 |
| Larrañaga, E | 1 |
| Orhan-Sungur, M | 1 |
| Akça, O | 1 |
| Dodek, P | 1 |
| Muscedere, J | 2 |
| Cook, D | 2 |
| Heyland, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study[NCT00934934] | Phase 2 | 61 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure (NCT00934934)
Timeframe: post randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 5.9 |
| Antifungal | 5.9 |
Number of days free of antibiotic use within the first 28 days (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Antifungal | 10 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 116 |
| VAP Without Candida | 129.1 |
(NCT00934934)
Timeframe: 28 days
| Intervention | mg/l (Mean) |
|---|---|
| VAP withCandida | 133 |
| VAP Without Candida | 145.7 |
Measure of the duration of participant stay in the ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 11.5 |
| Antifungal | 13 |
Measure of the duration of the participant's hospital stay (NCT00934934)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Placebo | 29 |
| Antifungal | 28 |
Number of days free of ICU (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 14 |
| Antifungal | 4 |
(NCT00934934)
Timeframe: 28 days
| Intervention | pg/ml (Mean) |
|---|---|
| VAP withCandida | 97.5 |
| VAP Without Candida | 3 |
Overall recruitment rate per site (NCT00934934)
Timeframe: 32 months
| Intervention | participants per site /month (Number) |
|---|---|
| Overall | 0.6 |
(NCT00934934)
Timeframe: 28 days
| Intervention | ng/ml (Mean) |
|---|---|
| VAP withCandida | 3.0 |
| VAP Without Candida | 22.5 |
Number of days in ICU free of ventilation (NCT00934934)
Timeframe: 28 days
| Intervention | days (Median) |
|---|---|
| Placebo | 8 |
| Antifungal | 9 |
2 trials available for ciprofloxacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Mi | 2008 |
Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial.
Topics: Aged; Anti-Infective Agents; Bronchoalveolar Lavage; Chi-Square Distribution; Ciprofloxacin; Drug Th | 2008 |
9 other studies available for ciprofloxacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Long | 2007 |
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Colistin; Drug Synergism; H | 2022 |
Fluoroquinolone resistance conferred by gyrA, parC mutations, and AbaQ efflux pump among Acinetobacter baumannii clinical isolates causing ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carrier Proteins; Ciproflo | 2019 |
Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftaz | 2017 |
Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Escherichia coli; Escherichia coli Infections | 2013 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; D | 2013 |
The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Matched | 2012 |
Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Female; Humans; Inciden | 2007 |
Ventilator-associated pneumonia by multidrug-resistant bacteria: pathogen-specific risks versus care-related risks.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multip | 2007 |